KYNTHEUM Solution for injection

Active ingredients: Brodalumab

Product name and form

Kyntheum 210 mg solution for injection in pre-filled syringe.

Pharmaceutical Form

Solution for injection (injection).

The solution is clear to slightly opalescent, colourless to slightly yellow and free from particles.

Qualitative and quantitative composition

Each pre-filled syringe contains 210 mg brodalumab in 1.5 ml solution. 1 ml solution contains 140 mg brodalumab.

Brodalumab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells.

For the full list of excipients, see section 6.1.

Active Ingredient

Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2 antibody that binds with high affinity to human IL-17RA and blocks the biological activities of the pro-inflammatory cytokines IL-17A, IL-17F, IL-17A/F heterodimer and IL-25, resulting in inhibition of the inflammation and clinical symptoms associated with psoriasis.

List of Excipients

Polysorbate 20
Water for injections

Pack sizes and marketing

1.5 ml solution in a type I glass pre-filled syringe with stainless steel 27G x ½" needle, covered with an elastomeric needle cap.

Kyntheum is available in unit packs containing 2 pre-filled syringes and in multipacks containing 6 (3 packs of 2) pre-filled syringes.

Not all pack sizes may be marketed.

Marketing authorization holder

LEO Pharma A/S, Industriparken 55, DK-2750, Ballerup, Denmark

Marketing authorization dates and numbers


Date of first authorisation: 17 July 2017


Austria, Estonia, Spain, Finland, France, Ireland, Lithuania, Netherlands, Poland, United Kingdom